Exploring the Association between Statin Use and the Risk of Parkinson's Disease: A Meta-Analysis of Observational Studies

Neuroepidemiology

Volumn 49, Issue 3-4, 2017, Pages 142-151

  Poly, Tahmina Nasrin ^a   Islam, Md Mohaimenul ^b   Walther, Bruno Andreas ^b   Yang, Hsuan Chia ^b   Nguyen, Phung Anh ^b   Huang, Chih Wei ^b   Shabbir, Syed Abdul ^b   Li, Yu Chuan Jack ^b,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Heterogeneity; Hypertension; Parkinson's disease; Statins; Stroke

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; ASIA; DRUG MONITORING; DRUG USE; EUROPE; HUMAN; KNOWLEDGE; NORTH AMERICA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHYSICIAN; QUALITY OF LIFE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; META ANALYSIS; RISK;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OBSERVATIONAL STUDIES AS TOPIC; PARKINSON DISEASE; RISK;

EID: 85039156497     PISSN: 02515350     EISSN: 14230208     Source Type: Journal    
DOI: 10.1159/000480401     Document Type: Article

References (39)

1. Pupillo E, Cricelli C, Mazzoleni F, Cricelli I, Pasqua A, Pecchioli S, Lapi F, Beghi E: Epidemiology of Parkinson's disease: a population-based study in primary care in Italy. Neuroepidemiology 2016; 47: 38-45.
2. Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T: The incidence of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology 2016; 46: 292-300.
3. Pringsheim T, Jette N, Frolkis A, Steeves TD: The prevalence of Parkinson's disease: A systematic review and meta-analysis. Mov Dis 2014; 29: 1583-1590.
4. Paganini-Hill A: Risk factors for Parkinson's disease: the leisure world cohort study. Neuroepidemiology 2001; 20: 118-124.
5. Baldi I, Cantagrel A, Lebailly P, Tison F, Dubroca B, Chrysostome V, Dartigues JF, Brochard P: Association between Parkinson's disease and exposure to pesticides in southwestern France. Neuroepidemiology 2003; 22: 305-310.
6. Preux P, Condet A, Anglade C, Druet-Cabanac M, Debrock C, Macharia W, Couratier P, Boutros-Toni F, Dumas M: Parkinson's disease and environmental factors. Neuroepidemiology 2000; 19: 333-337.
7. Chuang YH, Lill CM, Lee P-C, Hansen J, Lassen CF, Bertram L, Greene N, Sinsheimer JS, Ritz B: Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2. Neuroepidemiology 2016; 47: 192-200.
8. Becker C, Jick SS, Meier CR: Use of statins and the risk of Parkinson's disease. Drug Safety 2008; 31: 399-407.
9. Ritz B, Manthripragada AD, Qian L, Schernhammer E, Wermuth L, Olsen J, Friis S: Statin use and Parkinson's disease in Denmark. Mov Dis 2010; 25: 1210-1216.
10. Simon KC, Chen H, Schwarzschild M, Ascherio A: Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688-1695.
11. Henchcliffe C, Beal MF: Mitochondrial biology and oxidative stress in Parkinson's disease pathogenesis. Nat Rev Neurol 2008; 4: 600.
12. Danielson SR, Andersen JK: Oxidative and nitrative protein modifications in Parkinson's disease. Free Rad Biol Med 2008; 44: 1787-1794.
13. Selley ML: Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 2005; 1037: 1-6.
14. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C: Lower low-density lipoprotein cholesterol levels are associated with parkinson's disease. Mov Dis 2007; 22: 377-381.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The-PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6:e1000100.
16. Higgins JP, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, 2011.
17. de Lau LM, Stricker BH, Breteler M: Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson's disease. Mov Dis 2007; 22: 1985-1985.
18. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE: Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007; 5: 20.
19. Samii A, Carleton BC, Etminan M: Statin use and the risk of Parkinson's disease: a nested case control study. J Clin Neurosci 2008; 15: 1272-1273.
20. Gao X, Simon KC, Schwarzschild MA, Ascherio A: Prospective study of statin use and risk of Parkinson disease. Arch Neurol 2012; 69: 380-384.
21. Friedman B, Lahad A, Dresner Y, Vinker S: Long-term statin use and the risk of Parkinson's disease. Am J Manag Care 2013; 19: 626-632.
22. Huang X, Alonso A, Guo X, Umbach DM, Lichtenstein ML, Ballantyne CM, Mailman RB, Mosley TH, Chen H: Statins, plasma cholesterol, and risk of Parkinson,s disease: a prospective study. Mov Dis 2015; 30: 552-559.
23. Lin KD, Yang CY, Lee MY, Ho SC, Liu CK, Shin SJ: Statin therapy prevents the onset of Parkinson disease in patients with diabetes. Ann Neurol 2016; 80: 532-540.
24. Hippisley-Cox J, ζ C: Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340:c2197.
25. Lee YC, Lin CH, Wu RM, Lin MS, Lin JW, Chang CH, Lai MS: Discontinuation of statin therapy associates with Parkinson disease a population-based study. Neurology 2013; 81: 410-416.
26. Wahner AD, Bronstein JM, Bordelon YM, Ritz B: Statin use and the risk of Parkinson disease. Neurology 2008; 70: 1418-1422.
27. Undela K, Gudala K, Malla S, Bansal D: Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. J Neurol 2013; 260: 158-165.
28. Sheng Z, Jia X, Kang M: Statin use and risk of Parkinson's disease: a meta-analysis. Behav Brain Res 2016; 309: 29-34.
29. Hunot S, Hirsch E: Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003; 53(suppl 3):S49-S58
30. Kotagal V, Albin RL, Müller ML, Koeppe RA, Frey KA, Bohnen NI: Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology 2014; 82: 1514-1520.
31. Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B: Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 2011; 34: 1102-1108.
32. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW: Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia aging study. Mov Dis 2008; 23: 1013-1018.
33. Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E: Statins reduce neuronal α-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem 2008; 105: 1656-1667.
34. Brakedal B, Haugarvoll K, Tzoulis C: Simvastatin is associated with decreased risk of Parkinson disease. Ann Neurol 2017; 81: 329-330.
35. Hirtz D, Thurman D, Gwinn-Hardy K, Mohamed M, Chaudhuri A, Zalutsky R: How common are the "common" neurologic disorders? Neurology 2007; 68: 326-337.
36. Wong SL, Gilmour H, Ramage-Morin PL: Parkinson's disease: prevalence, diagnosis and impact. Health Rep 2014; 25: 10.
37. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J: Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007; 30: 842-847.
38. Sandyk R: The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 1993; 69: 125-130.
39. Leung HW, Chan AL, Lo D, Leung JH, Chen HL: Common cancer risk and statins: a population-based case-control study in a Chinese population. Exp Opin Drug Safety 2013; 12: 19-27.